Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study

Loïc Lelièvre , Philippe Clézardin (1) , Laurent Magaud , Laurent Roche (2) , Nicole Tubiana-Mathieu (3) , Jean-Dominique Tigaud , Delphine Topart (4) , Nadia Raban , Marie-Ange Mouret-Reynier (5) , Patrice Mathevet

1 LYOS - Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases
2 Service de Biostatistiques [Lyon]
3 Service d'Oncologie médicale [CHU Limoges]
4 Département d'oncologie médicale
5 IMoST - Imagerie Moléculaire et Stratégies Théranostiques

Neoadjuvant chemotherapy has become the treatment of choice for locally advanced breast cancer. Zoledronic acid (ZA) is a bisphosphonate initially used in the treatment of bone metastases because of its antibone resorption effect. Antitumor effects of ZA, including the inhibition of cell adhesion to mineralized bone or the antiangiogenic effect, have been demonstrated. However, the clinical significance of these effects remains to be determined.

Mots clés: Breast cancer; Locally advanced breast cancer; Neoadjuvant treatment; Vascular endothelial growth factor; Zoledronic acid

Domaines: Cancer

Loïc Lelièvre, Philippe Clézardin, Laurent Magaud, Laurent Roche, Nicole Tubiana-Mathieu, et al.. Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer, 2018, ⟨10.1016/j.clbc.2018.07.005⟩. ⟨hal-01930003⟩